Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.420
-0.010 (-0.41%)
At close: Dec 5, 2025, 4:00 PM EST
2.440
+0.020 (0.83%)
After-hours: Dec 5, 2025, 7:34 PM EST
Editas Medicine Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 4.13, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 70.66% from the current stock price of 2.42.
Analyst Consensus: Buy
* Price targets were last updated on Sep 5, 2025.
Analyst Ratings
The average analyst rating for Editas Medicine stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 6 | 5 | 5 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 12 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +106.61% | Sep 5, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | +65.29% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $5 | Strong Buy | Maintains | $3 → $5 | +106.61% | Aug 15, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +147.93% | Aug 13, 2025 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +65.29% | May 13, 2025 |
Financial Forecast
Revenue This Year
20.42M
from 32.31M
Decreased by -36.82%
Revenue Next Year
13.65M
from 20.42M
Decreased by -33.14%
EPS This Year
-2.06
from -2.88
EPS Next Year
-1.11
from -2.06
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 26.3M | 31.5M | ||||
| Avg | 20.4M | 13.7M | ||||
| Low | 16.0M | 2.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -18.8% | 54.3% | ||||
| Avg | -36.8% | -33.1% | ||||
| Low | -50.6% | -90.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.95 | -0.65 | ||||
| Avg | -2.06 | -1.11 | ||||
| Low | -2.09 | -1.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.